Skip to content

Novacure’s Wearable Lung Cancer Treatment Device, Optune Lua, Receives FDA Approval

 | 

The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell lung cancer (NSCLC). The device utilizes portable transducer arrays placed on the skin to deliver alternating electrical fields, termed Tumor Treating Fields (TTFs), thereby disrupting malignant cell division while leaving healthy cells largely unaffected.

Optune Luna was first approved in 2019 under the Humanitarian Device Exemption pathway in combination with chemotherapy to treat malignant pleural mesothelioma, a type of lung cancer that develops in the lining outside of the lungs and is typically attributed to asbestos exposure.

 The FDA’s recent approval was granted based on findings from the “Lunar” Phase 3 clinical trial. The study involved patients whose cancer had progressed following first-line platinum-based chemotherapy. The participants were randomly assigned to either receive TTF treatment with the Optune Luna device along with standard therapies—such as chemotherapy or PD-1 inhibitors like Merck & Co.’s Keytruda—or to receive standard therapies alone. Participants  using the device alongside standard therapies experienced a 26% lower risk of death during a median follow-up period of approximately 10 months.

Novocure’s TTField technology has also been used as a treatment for a rare type of brain cancer, glioblastoma multiforme (GBM). In 2011, the FDA approved Novacure’s Optune Gio device for treating the recurrence of GBM after treatment with chemotherapy.  The new FDA approval of Optune Lua opens up significant revenue potential for Novocure, by allowing it to enter the market for treating NSCLC, a more prevalent cancer type than GBM.

Novocure is exploring additional clinical opportunities for TTFs in other cancers, including brain metastases, gastric cancer, liver cancer, pancreatic cancer and ovarian cancer. While there are inherent clinical and regulatory risks, the positive track record of TTFs in trials may support future expansions in cancer treatment options.

Tags

, , , ,

Novacure’s Wearable Lung Cancer Treatment Device, Optune Lua, Receives FDA Approval Headshot

Raina Patel

Raina Patel is in the New York office and focuses primarily on patent prosecution and patent analysis. While most of her work is in the medical device space, she also has experience in the food/beverage, fashion, and consumer products industries. While in law school, Raina helped develop patent strategies for a wide variety of inventions while working at Boston University’s Office of Technology Development. She also worked with a biotech startup organizing and advancing their patent portfolio.

New York Bar Admission Pending

View all posts published by Raina Patel
By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.
close modal